NVTA · Invitae Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $121.24M | $120.53M | $117.36M | - | $133.54M | $136.62M | $123.69M | - | $114.39M | $116.31M |
| Cost of Revenue | $82.19M | $87.47M | $88.44M | - | $116.96M | $110.34M | $97.12M | - | $87.74M | $89.33M |
| Gross Profit | $39.05M | $33.06M | $28.91M | - | $16.58M | $26.28M | $26.57M | - | $26.65M | $26.98M |
| R&D | $58.34M | $63.82M | $61.98M | - | $87.18M | $115.15M | $128.24M | - | $97.51M | $106.45M |
| SG&A | $45.62M | $69.97M | $45.24M | - | $44.94M | $52.86M | $51.27M | - | $86.82M | $38.30M |
| Total Operating Expenses | $1.10B | $346.99M | $292.73M | - | $423.49M | ($12.30M) | $336.92M | - | - | - |
| D&A | $5.20M | $5.00M | $34.96M | - | $9.70M | $5.80M | $27.10M | - | $5.10M | $4.30M |
| Operating Income | ($980.19M) | ($226.46M) | ($175.37M) | - | ($289.95M) | ($2.52B) | ($213.23M) | - | ($193.31M) | $128.61M |
| Interest Expense | $5.85M | $6.02M | $11.50M | - | $14.14M | $14.02M | $13.98M | - | $14.07M | $13.41M |
| Income Tax | ($6.17M) | ($924.0K) | ($960.0K) | - | ($1.07M) | ($3.56M) | ($34.92M) | - | ($5.85M) | ($16.56M) |
| Net Income | ($942.11M) | ($206.51M) | ($192.18M) | - | ($301.16M) | ($2.52B) | ($181.86M) | - | ($198.18M) | $133.79M |
| EPS - Basic | ($3.42) | ($0.78) | ($0.77) | - | ($1.27) | ($10.87) | ($0.80) | - | ($0.91) | $0.66 |
| EPS - Diluted | ($3.42) | ($0.78) | ($0.77) | - | ($1.27) | ($10.87) | ($0.80) | - | ($0.91) | ($1.29) |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $158.01M | $222.76M | $161.20M | $257.49M | $217.03M | $303.63M | $325.33M | $923.25M | $921.63M | $1.11B |
| Accounts Receivable | $82.51M | $85.61M | $85.59M | $96.15M | $89.13M | $82.59M | $80.40M | $66.23M | $58.43M | $55.71M |
| Inventory | $21.63M | $20.81M | $19.07M | $30.39M | $29.90M | $49.07M | $43.46M | $33.52M | $30.63M | $29.98M |
| Accounts Payable | $25.18M | $23.07M | $11.90M | $13.98M | $10.73M | $26.75M | $41.70M | $21.13M | $35.40M | $31.24M |
| Current Assets | $378.40M | $451.23M | $504.27M | $693.13M | $729.68M | $894.25M | $1.03B | $1.18B | $1.37B | $1.64B |
| Total Assets | $535.12M | $1.52B | $1.69B | $1.95B | $2.03B | $2.29B | $4.77B | $4.92B | $5.07B | $5.00B |
| Current Liabilities | $158.42M | $151.97M | $190.18M | $108.09M | $113.32M | $139.25M | $167.90M | $144.09M | $156.17M | $133.64M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.62B | $1.72B | $1.73B | $1.85B | $1.87B | $1.90B | $1.92B | $1.94B | $1.96B | $2.34B |
| Stockholders' Equity | ($1.08B) | ($200.79M) | ($36.66M) | $101.84M | $158.87M | $385.90M | $2.84B | $2.98B | $3.11B | $2.65B |
| Retained Earnings | ($6.17B) | ($5.23B) | ($5.02B) | ($4.83B) | ($4.73B) | ($4.43B) | ($1.90B) | ($1.72B) | ($1.52B) | ($1.32B) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($34.40M) | - | - | - | ($147.54M) | - | - | - |
| Investing Cash Flow | - | - | $73.88M | - | - | - | ($449.46M) | - | - | - |
| Financing Cash Flow | - | - | ($135.77M) | - | - | - | ($920.0K) | - | - | - |
| CapEx | - | - | $1.32M | - | - | - | $20.85M | - | - | - |
| Free Cash Flow | - | - | ($35.72M) | - | - | - | ($168.39M) | - | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 32.2% | 27.4% | 24.6% | - | 12.4% | 19.2% | 21.5% | - | 23.3% | 23.2% |
| Operating margin | -808.5% | -187.9% | -149.4% | - | -217.1% | -1844.7% | -172.4% | - | -169.0% | 110.6% |
| EBITDA margin | -804.2% | -183.7% | -119.6% | - | -209.9% | -1840.5% | -150.5% | - | -164.5% | 114.3% |
| Net margin | -777.1% | -171.3% | -163.8% | - | -225.5% | -1847.0% | -147.0% | - | -173.2% | 115.0% |
| Free cash flow margin | - | - | -30.4% | - | - | - | -136.1% | - | - | - |
| FCF / Net income | - | - | 0.19 | - | - | - | 0.93 | - | - | - |
| R&D / Revenue | 48.1% | 53.0% | 52.8% | - | 65.3% | 84.3% | 103.7% | - | 85.2% | 91.5% |
| SG&A / Revenue | 37.6% | 58.0% | 38.6% | - | 33.7% | 38.7% | 41.5% | - | 75.9% | 32.9% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | -14.1% |
| Return on assets | -176.1% | -13.6% | -11.4% | - | -14.9% | -110.2% | -3.8% | - | -3.9% | 2.7% |
| Return on equity | 87.0% | 102.9% | 524.3% | - | -189.6% | -653.9% | -6.4% | - | -6.4% | 5.0% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.39 | 2.97 | 2.65 | 6.41 | 6.44 | 6.42 | 6.14 | 8.18 | 8.74 | 12.30 |
| Quick ratio | 2.25 | 2.83 | 2.55 | 6.13 | 6.18 | 6.07 | 5.88 | 7.95 | 8.55 | 12.08 |
| Cash ratio | 1.00 | 1.47 | 0.85 | 2.38 | 1.92 | 2.18 | 1.94 | 6.41 | 5.90 | 8.29 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -167.6x | -37.6x | -15.3x | - | -20.5x | -179.8x | -15.2x | - | -13.7x | 9.6x |
| Equity multiplier | -0.49 | -7.59 | -46.15 | 19.19 | 12.75 | 5.94 | 1.68 | 1.65 | 1.63 | 1.88 |
| Liabilities / Assets | 3.02 | 1.13 | 1.02 | 0.95 | 0.92 | 0.83 | 0.40 | 0.39 | 0.39 | 0.47 |
| Efficiency | ||||||||||
| Asset turnover | 0.23 | 0.08 | 0.07 | - | 0.07 | 0.06 | 0.03 | - | 0.02 | 0.02 |
| Inventory turnover | 3.80 | 4.20 | 4.64 | - | 3.91 | 2.25 | 2.23 | - | 2.86 | 2.98 |
| Days sales outstanding | 248d | 259d | 266d | - | 244d | 221d | 237d | - | 186d | 175d |
| Days inventory outstanding | 96d | 87d | 79d | - | 93d | 162d | 163d | - | 127d | 123d |
| Days payable outstanding | 112d | 96d | 49d | - | 33d | 88d | 157d | - | 147d | 128d |
| Cash conversion cycle | 233d | 250d | 296d | - | 303d | 294d | 244d | - | 167d | 170d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -9.2% | -11.8% | -5.1% | - | 16.7% | 17.5% | 19.4% | - | 66.4% | 151.8% |
| Revenue CAGR (3y) | 20.8% | 37.7% | 22.2% | - | 33.2% | 36.7% | 45.0% | - | 84.7% | 100.9% |
| Revenue CAGR (5y) | 46.2% | 53.1% | 33.5% | - | 49.1% | 57.0% | 64.3% | - | 120.7% | 83.6% |
| Gross profit growth (YoY) | 135.6% | 25.8% | 8.8% | - | -37.8% | -2.6% | -5.5% | - | 20.7% | 733.0% |
| Operating income growth (YoY) | -238.1% | 91.0% | 17.8% | - | -50.0% | - | -89.8% | - | -139.2% | - |
| Net income growth (YoY) | -212.8% | 91.8% | -5.7% | - | -52.0% | - | -66.1% | - | -92.6% | - |
| EPS growth (YoY) | -169.3% | 92.8% | 3.8% | - | -39.6% | -742.6% | 19.2% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 78.8% | - | - | - | -75.5% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | -96.6% | -94.9% | -85.5% | 19.7% | 50.7% | 645.8% | 471.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$738.64M totalDiagnostic Tests$444.07M · 60.1%
Test Revenue Centralized$276.92M · 37.5%
Collaboration And Genome Network$16.38M · 2.2%
Test Revenue Decentralized$1.28M · 0.2%
Geographic
$460.45M totalUS$404.01M · 87.7%
Rest Of World$48.88M · 10.6%
CA$7.55M · 1.6%
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing Invitae Corp against the 5 most active filers in the same SIC group.